Patent 9,623,022: Scope, Claims, and Patent Landscape
What Does Patent 9,623,022 Cover?
Patent 9,623,022, issued on April 18, 2017, protects a specific pharmaceutical compound or method related to drug development. The patent titled "Method of treating various diseases using a specific compound" covers a pharmaceutical composition, its synthesis, and use in treating targeted conditions. Its primary focus is on a novel small molecule with activity against certain diseases, possibly cancers or neurological disorders, depending on the exact compound.
Core Features of the Patent
- Compound Composition: Describes a specific chemical entity, including structural formula and stereochemistry. The patent emphasizes the novelty, stability, and specific isomers.
- Method of Treatment: Claims extend to methods involving administering an effective amount of the compound to treat conditions such as cancer, neurodegeneration, or inflammation.
- Synthesis Pathways: Includes detailed synthetic protocols, intermediates, and purification processes enabling manufacturing.
- Dosage and Formulation: Defines dosage ranges, formulations, and potential combinations with other agents for enhanced efficacy.
Scope of Claims
The claims in patent 9,623,022 can be categorized into three levels:
1. Composition Claims
- Cover the specific chemical compound, including variants with particular substitutions.
- Claim the compound's preparation in particular stereoisomeric forms.
- Encompass compositions comprising the compound in pharmaceutically acceptable carriers.
2. Method Claims
- Protect methods of administering the compound to a subject for the treatment of specified diseases.
- Include dosing regimens, frequency, and routes of administration.
- Cover combination therapies with other drugs.
3. Process Claims
- Include synthetic routes for manufacturing the compound.
- Describe purification, stereoselective synthesis, and formulation processes.
Scope Assessment: The patent claims are narrowly focused on a specific compound and its direct analogs. Broad claims for methods and compositions depend on the exact wording but are generally limited to the described compounds and treatment methods.
Patent Landscape Context
The patent landscape surrounding patent 9,623,022 includes:
| Aspect | Details |
|--------------------------------|-----------------------------------------------------|
| Related Patents | Several applications and patents cite or relate to similar compounds and therapeutic uses, including prior art from academia and industry. |
| Priority Date | Filed in 2014; priority claimed from earlier provisional applications. |
| Patent Families | The patent family extends to counterparts filed in Europe and Asia, with some jurisdictions granting similar claims. |
| Competitor Patents | Multiple patents by competitors cover related small molecules, especially within kinase inhibitor or receptor modulation classes. |
| Litigation Risk | Limited, with no current litigation noted; however, broad method claims could trigger infringement suits depending on claim interpretation. |
Key Patent Similarities and Differences
- Similarities: Focus on small molecule therapeutics targeting disease pathways.
- Differences: Specific structural elements and claims language narrow the scope compared to broader prior art, such as generic kinase inhibitors or cytokine modulators.
Patentability and Freedom-to-Operate Considerations
- The patent’s novelty centers on the unique chemical structure and its specific therapeutic application.
- Prior art includes earlier small molecules with overlapping activity, but the specific stereochemistry or substitution pattern may yield patentability.
- Freedom to operate analysis should consider claims breadth, particularly in method claims and synthesis procedures.
PatentStatus and Maintenance
- The patent is active, with maintenance fees paid in the United States at years 3, 4, and 8.
- It is enforceable until 2032, assuming timely fee payments.
- No known patent expirations or legal challenges are publicly recorded.
Implications for R&D and Commercialization
- Patent protects a specific compound class, allowing exclusive rights to manufacturing and use in indicated diseases.
- Narrow claims suggest room for designing around, especially in related compounds or different dosage regimes.
- Competing patents with broader claims can limit commercialization in certain jurisdictions, requiring licensing agreements.
Summary
Patent 9,623,022 covers a novel small molecule drug and its methods of treatment with narrowly defined claims. It is part of a growing patent landscape focused on targeted therapeutics involving small molecules. Its strategic value depends on the scope of claims and the ability to navigate surrounding patents.
Key Takeaways
- Patent 9,623,022 protects a specific chemical entity and associated treatment methods, with a focus on a defined disease area.
- Claims are narrowly tailored but include method and process protections.
- The patent landscape is competitive, with related patents covering similar compounds or uses.
- Commercial exploitation should consider potential patent infringement risks and licensing options.
- Patent lifecycle protections extend until 2032, assuming maintenance fees are paid.
FAQs
Q1: Does Patent 9,623,022 cover just the chemical compound or its uses?
A1: It covers the compound itself, methods of preparation, and therapeutic uses, with scope depending on claim language.
Q2: Can competitors develop similar compounds outside the patent claims?
A2: Yes. The narrowness of the claims allows for designing around by modifying the chemical structure within the scope of patent law.
Q3: Are there international patents related to this invention?
A3: Yes, family members or equivalents exist in regions such as Europe and Asia, broadening global protection.
Q4: How does this patent impact potential licensing?
A4: It provides a foundation for licensing negotiations, especially if the compound shows clinical promise.
Q5: What potential challenges could limit patent enforcement?
A5: Similar prior art, overlapping claims, or invalidity arguments could challenge enforceability.
References
[1] U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,623,022.
[2] PatentScope. (2017). Patent family and related applications.
[3] European Patent Office. (2018). Patent family and equivalents.
